Officials at x-ray manufacturer Del Global Technologies believe the company has added an important European dimension to its Valhalla, NY-based business by increasing its ownership in Villa Sistemi Medicali, an Italian radiographic/fluoroscopic firm.In
Officials at x-ray manufacturer Del Global Technologies believe the company has added an important European dimension to its Valhalla, NY-based business by increasing its ownership in Villa Sistemi Medicali, an Italian radiographic/fluoroscopic firm.
In January, Del Global obtained a 19% stake in Villa along with the nonrevocable option to increase its share to 80%.
In April, Del Global decided to exercise its option.
Villa Sistemi has annual sales of $20 million. Its line of radiographic/fluoroscopic systems and a line of portable imaging systems with power ratings up to 30 kW complements Del Globals existing line of products, said Leonard Trugman, Del Globals president.
Getting into the European imaging market has been one of Del Globals goals over the last five years, Trugman said. Before the Villa Sistemi acquisition, medical salessystems and subsystemsaccounted for 80% of Del Globals total sales (SCAN 2/2/00). The acquisition drives that to 90%.
Prior to 1990, Del Global manufactured mostly defense electronics.
The company shifted toward medical imaging in the early 1990s, primarily by acquiring companies that specialized in niche technologies Del Global lacked (SCAN 2/2/00).
Del Global purchased x-ray and mammography firm DynaRad in 1992, and in 1996 bought Gendex Medical from Dentsply International. In 1998, Del Global acquired Acoma Medical Imaging for $1.4 million. That year, the company posted the strongest fourth-quarter and fiscal-year results in its history. Year-end sales for 1998 were $62.3 million (SCAN 11/11/98).
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.